Review
Oncology
Yonghao Sun, Zuoxing Xue, Tao Huang, Xiangyu Che, Guangzhen Wu
Summary: Ferroptosis is a type of regulated cell death mediated by lipid peroxidation and iron dependence, which is closely associated with various diseases, including cancer. Changes in lipid metabolism, such as lipid peroxidation and ferroptosis, play critical roles in cancer therapy. This review provides an overview of the characteristics of ferroptosis and analyzes the connections between several metabolic mechanisms and ferroptosis. The effects of lipid peroxides, signaling pathways, and molecules involved in lipid metabolism on ferroptosis are extensively discussed. Furthermore, the review highlights ferroptosis-based treatments and provides examples of their combination with other therapies.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Hongying Lan, Yu Gao, Zhengyang Zhao, Ziqing Mei, Feng Wang
Summary: This review summarizes the recent progress in the molecular regulation of ferroptosis and discusses the physiological roles and therapeutic potential of targeting ferroptosis in hematological malignancies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ben Che, Yunyan Du, Rongfa Yuan, Han Xiao, Wenming Zhang, Jun Shao, Hongcheng Lu, Yi Yu, Mingfeng Xiang, Liang Hao, Shouhua Zhang, Xiaohong Du, Xiuxia Liu, Wei Zhou, Kai Wang, Leifeng Chen
Summary: This study reveals that SLC35F2 inhibits ferroptosis in pancreatic cancer cells by facilitating TRIM59-mediated p53 degradation, and SLC35F2 emerges as a promising therapeutic target for treating pancreatic cancer.
Article
Biochemistry & Molecular Biology
Ben Che, Yunyan Du, Rongfa Yuan, Han Xiao, Wenming Zhang, Jun Shao, Hongcheng Lu, Yi Yu, Mingfeng Xiang, Liang Hao, Shouhua Zhang, Xiaohong Du, Xiuxia Liu, Wei Zhou, Kai Wang, Leifeng Chen
Summary: This study reveals the role of SLC35F2 in inhibiting ferroptosis in pancreatic cancer cells and highlights the involvement of p53 in this process. The elevated expression of SLC35F2 in pancreatic cancer tissues is associated with adverse survival outcomes. Additionally, the study identifies irinotecan hydrochloride and lapatinib ditosylate as potential compounds targeting SLC35F2 to enhance the antitumor effect of imidazole ketone erastin in wild-type p53 patient-derived xenograft model.
Review
Cell Biology
Yini Liu, Chunyan Duan, Rongyang Dai, Yi Zeng
Summary: Ferroptosis, a form of non-apoptotic regulated cell death primarily driven by iron-dependent lipid peroxidation, plays a significant role in cancer biology. Characterized by the accumulation of lipid peroxides and lethal reactive oxygen species, it differs from other types of cell death and can modulate cancer progression by reprogramming the tumor microenvironment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Hong-Tao Wang, Jie Ju, Shao-Cong Wang, Yu-Hui Zhang, Cui-Yun Liu, Tao Wang, Xue Yu, Fei Wang, Xue-Ru Cheng, Kun Wang, Zhao-Yang Chen
Summary: Ferroptosis is a novel form of cell death characterized by iron accumulation and redox imbalance. It has unique morphological and biochemical features and shows great potential in cancer treatment. Small molecules based on research by Brent R. Stockwell's lab have been developed to induce ferroptosis in cancer cells, and some FDA-approved drugs have been found to trigger ferroptosis as well. Radiotherapy and checkpoint therapy have also been found to induce ferroptosis, providing new strategies for cancer treatment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Huocheng Yang, Xuemei Yao, Yingqi Liu, Xinkun Shen, Menghuan Li, Zhong Luo
Summary: Ferroptosis, a regulated cell death driven by iron-dependent phospholipid peroxidation, has gained attention in nanomedicine since 2012. It has unique features compared to other cell death modes and shows promise in treating resistant cancers. Recent insights suggest its connection to the tumor immune microenvironment, indicating its potential in stimulating antitumor immunity. Understanding the relationship between tumor metabolism and ferroptosis is important for developing antitumor therapies.
Article
Oncology
Lianxiang Luo, Han Wang, Wen Tian, Jiayan Zeng, Yuru Huang, Hui Luo
Summary: Ferroptosis is a newly discovered form of programmed cell death that relies on iron-dependent lipid peroxidation accumulation, playing a crucial role in cancer biology. Understanding the regulatory mechanisms of ferroptosis, its impact on tumor cell metabolism, and anti-tumor immunity is essential for future research in utilizing targeted regulation of iron and iron-dependent regulation of ferroptosis in cancer therapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Haixia Ji, Wenzhe Wang, Xia Li, Xiaoying Han, Xinyu Zhang, Juan Wang, Changxiao Liu, Luqi Huang, Wenyuan Gao
Summary: This review discusses the role of the p53 gene in regulating ferroptosis, primarily through influencing metabolic networks and signaling pathways that affect tumor cell sensitivity to ferroptosis. This has important implications for further understanding the role of p53 in tumor ferroptosis and developing new strategies for cancer treatment.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Oncology
Shuyue Zheng, Xin-Yuan Guan
Summary: Ferroptosis is a cell death that occurs due to the accumulation of ferrous ions and lipid peroxidation in tumor cells. Targeting ferroptosis as a novel strategy for anti-tumor therapy involves regulating various metabolic and immune elements. This review highlights the mechanism of ferroptosis, its interaction with cancer and tumor immune microenvironment, particularly the relationship between immune cells and ferroptosis. Additionally, it discusses the latest preclinical progress in combining ferroptosis-targeted drugs with immunotherapy, and the optimal conditions for their combined use, providing insight into the potential value of ferroptosis in cancer immunotherapy.
Review
Oncology
Guang Lei, Li Zhuang, Boyi Gan
Summary: This article provides an overview of the importance and potential of ferroptosis in cancer research, summarizes the mechanisms of ferroptosis induction and defense, analyzes its roles and mechanisms in tumor suppression and tumor immunity, and explores therapeutic strategies targeting ferroptosis in cancer.
NATURE REVIEWS CANCER
(2022)
Review
Materials Science, Biomaterials
Weimin Yin, Jiao Chang, Jiuyuan Sun, Tingting Zhang, Yuge Zhao, Yongyong Li, Haiqing Dong
Summary: Apoptosis-based treatment is important in regulating tumor cell death, but cancer cells can escape this process, leading to resistance to therapies. Ferroptosis, a newly identified type of cell death, has sparked interest in cancer therapy. Nanomedicine-mediated strategies for inducing ferroptosis have shown promising results in targeted and enhanced tumor treatment. This review provides an overview of state-of-the-art research on nanomedicine-mediated ferroptosis targeting strategies for synergistic cancer therapies, as well as the potential mechanisms involved. The future development of nanomedicine in the field of ferroptosis-based cell death in tumor treatment is also discussed.
JOURNAL OF MATERIALS CHEMISTRY B
(2023)
Review
Oncology
Yong Liu, Zefan Du, Junbin Huang, Tianwen Li, Jing Zhang, Yixian Li, Wenfang Yi, Chun Chen
Summary: Ferroptosis, an iron-dependent programmed cell death, has been discovered in recent years. It is characterized by the accumulation of lipid reactive oxygen species in cells, leading to oxidative stress and cell death. It plays a pivotal role in normal physiology and the development of various diseases.
FRONTIERS IN ONCOLOGY
(2023)
Editorial Material
Chemistry, Multidisciplinary
Yu Wang, Tao Sun, Chen Jiang
Summary: This review summarizes NDDSs designs driven by different metabolic pathways, emphasizes the feasibility of inducing ferroptosis in cancer treatment, and discusses the limitations of NDDSs and future developments in the field.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Pharmacology & Pharmacy
Nadia Zaffaroni, Giovanni Luca Beretta
Summary: Nanoparticles inducing ferroptosis show potential for cancer therapy with advantages over small molecules. They can load drugs, target tumors, and have other therapeutic applications.
Article
Biotechnology & Applied Microbiology
Jian Xu, Yan Su, Aoshuang Xu, Fengjuan Fan, Shidai Mu, Lei Chen, Zhangbo Chu, Bo Zhang, Haifan Huang, Jiasi Zhang, Jun Deng, Lisha Ai, Chunyan Sun, Yu Hu
Article
Oncology
Qianwen Cheng, Li Cai, Yuyang Zhang, Lei Chen, Yu Hu, Chunyan Sun
Summary: Circulating plasma cells (CPC) were found to be an independent prognostic factor for patients with newly diagnosed multiple myeloma (NDMM). Nomograms predicting progression-free survival (PFS) and overall survival (OS) were successfully developed based on CPC, lactate dehydrogenase (LDH), and creatinine levels, providing effective risk stratification and individualized survival predictions.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xuejiao Yin, Aoshuang Xu, Zhenli Huang, Fengjuan Fan, Yajun Wang, Lei Chen, Guohui Cui, Yu Hu, Chunyan Sun
Summary: The study found that DLBCL patients with different primary extranodal sites have significantly different risks of developing SMNs, with the risk increasing over time and showing specific patterns for different sites. The initial site of DLBCL may predict the type of SMN, suggesting individualized cancer surveillance strategies may be needed based on the subsite of extranodal DLBCL.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Hematology
Chunyan Sun, Jian Xu, Bo Zhang, Haifan Huang, Lei Chen, Han Yan, Aoshuang Xu, Fei Zhao, Daijuan Huang, Liqiong Liu, Jian Li, Yu Hu
Summary: TEMPI syndrome is a newly defined multisystemic disease with unknown pathophysiology. The study identified somatic nonsynonymous single-nucleotide variants, complex structural variants of chromosome 2, and the upregulated expression of macrophage migration inhibitory factor (MIF) in patients with TEMPI syndrome. The level of serum MIF was significantly decreased in one patient after treatment with plasma cell-directed therapy, indicating a potential role of MIF in the pathophysiology of TEMPI syndrome.
Article
Immunology
Qianwen Cheng, Fei Zhao, Bo Zhang, Yuyang Zhang, Li Cai, Bing Qiao, Yu Hu, Chunyan Sun
Summary: This study aimed to explore the relationship between pretreatment cytokine status and overall survival in newly diagnosed multiple myeloma (NDMM) patients, and established a prognostic nomogram incorporating cytokines. Using multivariate Cox analysis, three key variables (lactate dehydrogenase, MIP-1 alpha, and creatinine) were included in the nomogram. The nomogram showed superior predictive power for overall survival compared to existing staging systems, accurately predicting 1-year, 2-year, and 3-year survival rates for NDMM patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Aoshuang Xu, Jiasi Zhang, Liping Zuo, Han Yan, Lei Chen, Fei Zhao, Fengjuan Fan, Jian Xu, Bo Zhang, Yuyang Zhang, Xuejiao Yin, Qianwen Cheng, Su Gao, Jun Deng, Heng Mei, Zhiping Huang, Chunyan Sun, Yu Hu
Summary: This study reveals the role of N-6-methyladenosine (m(6)A) in multiple myeloma (MM) pathogenesis and identifies fat mass and obesity-associated protein (FTO) as a crucial regulator. FTO plays a tumor-promoting and pro-metastatic role in MM through targeting heat shock factor 1 (HSF1)/heat shock proteins (HSPs) in a YTHDF2-dependent manner. The inhibition of FTO, especially in combination with bortezomib (BTZ) treatment, shows synergistic effects in inhibiting myeloma bone tumor formation and extramedullary spread. The study suggests FTO-HSF1/HSP axis as a potential therapeutic target in MM.
Review
Endocrinology & Metabolism
Jian Xu, Wenqi Liu, Fengjuan Fan, Bo Zhang, Fei Zhao, Yu Hu, Chunyan Sun
Summary: TEMPI syndrome is a rare and newly defined multisystemic disease, and its etiology, pathogenesis, and clinical features are largely unknown. Missed diagnosis and misdiagnosis are common due to its diverse and hidden clinical manifestations. Recent studies have reported special clinical manifestations and attempted to identify the pathogenesis of TEMPI syndrome.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Oncology
Chunyan Sun, Xiaohong Wang, Renyi Zhang, Lingjie Xu, Bin Wang, Jian Li
Summary: This systematic review and meta-analysis investigated the efficacy and safety of intravenous daratumumab (DARA IV) for the treatment of amyloid light-chain (AL) amyloidosis. The results showed that DARA IV treatment had a good response rate and survival rate for patients.
CANCER CELL INTERNATIONAL
(2022)
Review
Oncology
Guangqi Wang, Fengjuan Fan, Chunyan Sun, Yu Hu
Summary: This article summarizes the issues of relapses and drug resistance in the treatment of multiple myeloma (MM) patients and discusses novel therapeutic strategies to improve clinical outcomes by targeting endoplasmic reticulum stress (ERS) response.
Article
Oncology
Bing Qiao, Lei Chen, Qianwen Cheng, Guangqi Wang, Qun Li, Bo Zhang, Junying Li, Yu Hu, Chunyan Sun
Summary: The aberrant expression of CCL18 is an independent prognostic factor for multiple myeloma. High levels of CCL18 are associated with renal impairment, hypercalcemia, and a lower proportion of complete remission. The expression of CCL18 is also associated with the survival period of MM patients.
Article
Oncology
Jiasi Zhang, Yuxi Liu, Qun Li, Liping Zuo, Bo Zhang, Fei Zhao, Fengjuan Fan, Shanshan Luo, Yu Hu, Chunyan Sun
Summary: ACSL4 is abnormally overexpressed in multiple myeloma (MM) and plays a role in regulating lipid metabolism genes and determining the sensitivity of MM cells to ferroptosis. Targeting ACSL4 and inducing ferroptosis could be a promising therapeutic strategy for MM.
Review
Medicine, Research & Experimental
Weizhuo Lu, Zhiwu Chen, Jiyue Wen
Summary: Ischemic stroke is a common and serious disease, and neuroinflammation plays a crucial role in its progression. Microglia, astrocytes, and infiltrating immune cells are involved in the complicated neuroinflammation cascade, releasing different molecules that affect inflammation. Flavonoids, plant-specific compounds, have shown protective effects against cerebral ischemia injury by modulating the inflammatory responses.
BIOMEDICINE & PHARMACOTHERAPY
(2024)
